PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
J Immunol. Author manuscript; available in PMC 2012 July 25.
Published in final edited form as:
PMCID: PMC3404409
NIHMSID: NIHMS389340

Decreased Levels of Secretory Leucoprotease Inhibitor in the Pseudomonas-infected Cystic Fibrosis Lung are due to Neutrophil Elastase Degradation1

Abstract

Secretory leucoprotease inhibitor (SLPI) is a neutrophil serine protease inhibitor constitutively expressed at many mucosal surfaces including that of the lung. Originally identified as a serine protease inhibitor, it is now evident that SLPI also has anti-microbial and anti-inflammatory functions, and therefore plays an important role in host defence. Previous work has shown that some host defence proteins such as SLPI and elafin are susceptible to proteolytic degradation. Consequently, we investigated the status of SLPI in the Cystic Fibrosis (CF) lung. A major factor that contributes to the high mortality rate among CF patients is Pseudomonas aeruginosa infection. In this study, we report that P. aeruginosa-positive CF bronchoalveolar lavage fluid (BALF), which contains lower SLPI levels and higher neutrophil elastase (NE) activity compared to P. aeruginosa-negative samples, was particularly effective at cleaving recombinant human SLPI. Additionally, we found that only NE inhibitors were able to prevent SLPI cleavage, thereby implicating NE in this process. NE in excess was found to cleave recombinant SLPI at two novel sites in the NH2-terminal region and abrogate its ability to bind LPS and NF-κB consensus binding sites but not its ability to inhibit activity of the serine protease cathepsin G. In conclusion, this study provides evidence that SLPI is cleaved and inactivated by NE present in P. aeruginosa-positive CF lung secretions and that P. aeruginosa infection contributes to inactivation of the host defence screen in the CF lung.

Introduction

Cystic Fibrosis (CF)3 is an autosomal recessive disease caused by loss of expression/function mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Lung disease causes 95% of the morbidity and mortality in CF patients and is associated with the failure of pulmonary innate immune functions leading to a vicious cycle of continual infection, inflammation and remodelling of lung tissue (1). A major factor that contributes to this mortality rate is infection with Pseudomonas aeruginosa. Once chronic infection is established, it is virtually impossible to eradicate and is associated with reduced survival (2,3). Another contributing factor is the presence of large numbers of neutrophils and ensuing high concentrations of neutrophil proteases, particularly neutrophil elastase (NE), in the airways of CF patients which overwhelm the host’s antiprotease screen (1). Over the past three decades it has become clear that a number of proteins involved in defending the lung against proteases possess multiple, yet seemingly independent, functions which under normal circumstances serve to protect the lung from infection and inflammation as well as protease-induced degradation.

One such protein is human secretory leucoprotease inhibitor (SLPI), a cationic 11.7 kDa serine protease inhibitor constitutively expressed at mucosal surfaces, primarily the upper respiratory tract. SLPI consists of 107 amino acids organised in two whey acidic protein (WAP) four disulfide core (WFDC) domains, each with four disulfide bridges (4,5). SLPI is produced by a number of cell types including neutrophils, macrophages and epithelial cells and expression can be altered by various stimuli including LPS (6,7), NE (8,9) and both pro-and anti-inflammatory cytokines (10,11). Overall, the evidence to date suggests that the function of SLPI is to protect local tissue from the detrimental consequences of inflammation not only as a result of its well documented antiprotease activities but also via its antimicrobial and anti-inflammatory properties. SLPI can inhibit a variety of proteases released during inflammation such as elastase, cathepsin G, trypsin, chymotrypsin, chymase and tryptase (12). Meanwhile, a number of studies have found that SLPI displays antimicrobial effects against pathogens such as Escherichia coli, P. aeruginosa and Staphylococcus aureus, and also inhibits the growth of fungi such as Aspergillus fumigatus and Candida albicans (1315).

SLPI also possesses immunomodulatory activity both in vivo and in vitro. Administration of aerosolised SLPI to CF patients suppressed levels of both NE and IL-8 in the lung (16,17). In response to LPS, SLPI deficient mice show increased mortality from endotoxin shock (18). Furthermore, in a mouse model of acute lung injury, prior administration of SLPI decreased lung injury and down-regulated NF-κB activation by preventing degradation of the NF-κB inhibitor protein, IκBβ (19,20). These findings have been confirmed in vitro and mechanisms of action continue to be elucidated. SLPI binds bacterial LPS extracellularly thereby down-regulating the uptake of LPS and subsequent production of pro-inflammatory mediators (2123). However, as a consequence of the internalisation of SLPI into the cytoplasm and nucleus of cells such as monocytes, it appears that SLPI also has intracellular sites of action (24). In the cytoplasm, SLPI inhibited LPS and lipoteichoic acid (LTA)-induced NF-κB activation in human monocytes, by preventing degradation of key regulatory proteins such as IκBα, IκBβ and interleukin-1 receptor activated kinase (IRAK) (25,26). In addition, previous findings from our group have shown that SLPI also exerts effects on NF-κB signalling cascade in the nucleus of monocytes, where SLPI can compete with p65 for binding to the NF-κB binding sites in the promoter regions of pro-inflammatory genes such as IL-8 and TNF-α (24).

Although SLPI can inhibit a variety of proteases released during inflammation, it appears that SLPI levels and activity may be compromised in numerous disease states where the body is overwhelmed by infection and concomitant proteases. Evidence of SLPI cleavage has been reported in individuals with frequent chronic obstructive pulmonary disease (COPD) exacerbations (27), emphysema (28) and CF (29). It has become clear that SLPI and other important host defence proteins are susceptible to proteolytic cleavage by a range of proteases of both endogenous and bacterial origin. We have previously shown that cysteine proteases called cathepsins cleave and inactivate SLPI and human β-defensins in epithelial lining fluid from individuals with emphysema (28) and CF (30), respectively, while cathepsin-mediated degradation of lactoferrin was observed in P. aeruginosa-infected CF sputum and BALF (31). In addition, exogenous elastolytic proteases of bacterial origin may play a role in the cleavage and inactivation of host defence molecules. For example, Pseudomonas elastase or pseudolysin has been shown to cleave SLPI (32), and high concentrations of pseudolysin, Pseudomonas alkaline protease and NE were also able to inactivate lactoferrin (33).

Recent findings from our lab have demonstrated that recombinant human elafin (another well-characterised WFDC-containing protein found in the lung) is cleaved by NE in CF sputum and that P. aeruginosa infection promotes this degradation (34). In the present study, we expand this research to investigate the hypothesis that the high levels of NE present in the P. aeruginosa-infected CF lung correlate with low levels of SLPI and that NE is responsible for cleaving and inactivating the multifunctional, host defence protein SLPI. Our findings show that Pseudomonas infection increases NE levels which subsequently cleave SLPI in the CF lung and may have repercussions on the innate immune functions of this protein.

Materials and Methods

Materials

Recombinant human SLPI was obtained from Amgen. Biotinylated anti-human SLPI antibody was purchased from R&D Systems (Abingdon, Oxon, UK). N-(Methoxysuccinyl)-Ala-Ala-Pro-Val-chloromethyl ketone (MeOSuc-AAPV-CMK or CMK) and EDTA were purchased from Sigma-Aldrich (Poole, Dorset, UK). Alpha-1-antichymotrypsin (ACT), N-(Methoxysuccinyl)-Ala-Ala-Pro-Val-paranitroanilide (MeOSuc-AAPV-pNA), N-(Methoxysuccinyl)-Ala-Ala-Pro-Met-paranitroanilide (MeOSuc-AAPM-pNA), cathepsin G (CatG) and E64 were purchased from Merck Biosciences. Human neutrophil elastase (NE) was from Elastin Products Company, Inc. (Owensville, MO, USA). Human proteinase 3 (Pr3) was from Athens Research (Athens, GA, USA). Horseradish peroxidase (HRP)-conjugated streptavidin was obtained from Biolegend (San Francisco, CA, USA). SuperSignal West Femto Maximum Sensitivity Substrate was purchased from Pierce. All other reagents were of analytical grade.

CF bronchoalveolar lavage fluid processing

We studied a total of 26 patients diagnosed with CF (F508del), 15 with P. aeruginosa infection and 11 without (Table I). CF bronchoalveolar lavage fluid (BALF) samples were obtained from individuals undergoing flexible bronchoscopy for clinical reasons. Ethical approval for the use of these samples was obtained from the institutional review board of the Adelaide and Meath Hospital incorporating the National Children’s Hospital. Bronchoscopy was performed via a laryngeal mask airway. The bronchoscope was directed to the lingula and right middle lobe. Bronchoalveolar lavage was performed by instilling 1 ml/kg of sterile normal saline per lobe. Return was typically in the region of 40%. Specimens from right and left were pooled. BALF was centrifuged at 4000 rpm for 10 min and the supernatant aliquoted and stored at −80°C. Bacteria were cultured from the BALF sample on the day of the procedure.

Table I
Clinical information for patients included in the studya

Determination of SLPI levels in Pseudomonas positive and negative CF BALF

SLPI levels were determined by ELISA. Rabbit anti-human SLPI (1:1000 in Voller’s buffer) was added to Maxisorp 96-well plates (Nunc) and left overnight at 4°C. The plate was washed three times with PBS/0.05% (v/v) Tween 20 (PBST) and blocked in PBST containing 1% BSA for 1 h at room temperature. After washing three times in PBST, SLPI standards (26 pM to 1.66 nM) and CF BALF samples (100 μl per well of 1:100 diluted (SLPI) were added in 100 μl aliquots to the plate for 2 h at room temperature. The plate was then washed and biotinylated anti-human SLPI antibody (R&D Systems, 1:1000 in PBST) was added to the plate for 2 h at room temperature. After washing, the plates were incubated with HRP-conjugated streptavidin (1:2500 in PBST) for 20 min at room temperature and washed with PBST. After the third wash, peroxidase activity was measured by the addition of substrate (ABTS Single Solution, Zymed® Laboratories). The A405 of the wells were measured on a microtitre plate reader (Genios using Magellan software) and results were converted to SLPI concentrations (ng/ml) using GraphPad Prism, version 5.1 (GraphPad Software, San Diego).

Western blot analysis of SLPI in CF BALF

Individual P. aeruginosa positive and negative CF BALF (20 μl) samples were separated by denaturing SDS-PAGE using 15% polyacrylamide gels and blotted onto nitrocellulose membrane (Sigma-Aldrich). The membrane was blocked for 1 h at room temperature with 3% BSA in PBS containing 0.1% (v/v) Tween 20. SLPI was detected using a biotinylated anti-SLPI antibody (R&D Systems, 1:500, overnight at 4°C with shaking) followed by incubation with peroxidase-conjugated streptavidin (1:2500, 20 min at room temperature). Peroxidase activity was detected using the chemiluminescent SuperSignal West Femto Maximum Sensitivity Substrate and analysed using the Syngene GeneSnap and GeneTools software on the ChemiDoc system.

Western blot analysis of recombinant SLPI incubated with CF BALF and human proteases

Recombinant SLPI (0.166 μM) was incubated with 10 μl CF BALF in 30 mM TBS (pH 7.5) in a final volume of 20 μl for 0, 10 min, 1 h, 6 h or 24 h at 37°C. To test effects of pH on SLPI degradation by CF BALF, some incubations were carried out at pH 5.5 as depicted in the figure legends. In some cases, CF BALF was pre-incubated for 1 h at 37°C with the following protease inhibitors before adding SLPI: 1 mM PMSF, 13 mM EDTA, 0.4 mM E64, 1 μM ACT, 1 μM elafin or 0.1 mM MeOSuc-AAPV-CMK). Additionally, recombinant SLPI (0.42 μM) was incubated with various concentrations of NE, Pr3 or CatG (from 16 nM to 4.2 μM) for 24 h in TBS in a 20 μl volume at 37°C. All incubations were stopped by adding sample treatment buffer containing reducing agent and boiling for 5 min. Samples were separated by SDS-PAGE using a 15% polyacrylamide gel and blotted onto nitrocellulose membrane (Sigma-Aldrich). SLPI was detected as described above.

Measurement of elastase activity in CF BALF

P. aeruginosa positive and negative CF BALF (10 μl) were diluted in 0.1 M Hepes, 0.5 M NaCl, pH 7.5 containing 0.13 mM E64, 0.11 mM pepstatin A and 5.4 mM EDTA and treated with or without NE inhibitor (1 mM MeOSuc-AAPV-CMK) for 1 h at 37°C in a 100 μl volume. The chromogenic substrate, MeOSuc-AAPV-pNA (50 μl), was mixed with each sample to a final concentration of 1.4 mM and absorbance at 405 nm was measured over the time at 37°C in a 96-well microplate reader (Genios using Magellan software). The activity of NE in samples was determined by comparing the elastase activity (given by the rate of hydrolysis of the substrate) with a standard curve of purified NE. All measurements were performed in duplicate.

HPLC mass spectrometry

Cleavage of SLPI by NE was assessed by incubating recombinant SLPI (2 μM) with NE (8 μM) for 1 h in 0.1 M Hepes/0.5 M NaCl pH 7.5 in 40 μl final volume at 37°C. Elastase activity was neutralised with 1 μl PMSF (100 mM) for 30 min at room temperature. Samples were lyophilised until analysis when they were redissolved in 10 μl 6 M guanidine HCl, 100 mM Tris pH 8.5, 1 mM EDTA. One μl 10% trifluoroacetic acid was added to each sample to bring the pH to <3. Samples were then analyzed by reverse phase HPLC coupled to electrospray mass spectrometry as described (34).

LPS ELISA

A Maxisorp plate (Nunc) was coated with 100 ng/well P. aeruginosa LPS (P. aeruginosa serotype 10, Sigma Aldrich) diluted in serum free RPMI media (SFM) and incubated at 37°C for 3 h. Unbound LPS was washed off the plate with distilled water and the plate was left to air-dry overnight at room temperature. The next day, the plate was blocked with 1% BSA in PBS for 2 h at room temperature. The plate was washed three times with PBS/0.05 % (v/v) Tween. Samples (100 μl/well) were added to the plate (0.42 μM SLPI alone, 0.42 μM of SLPI incubated with 1.68 μM NE) and diluted 1:2 in SFM across the plate followed by incubation for 2 h. Control wells received SFM alone. Again, the plate was washed three times before adding biotinylated anti-SLPI IgG (1:1000) and incubating for 2 h. After washing, streptavidin peroxidase (1:2500) was added to the plate for 20 min. After washing, ABTS Single Solution substrate (Zymed® Laboratories) was added and the plate was incubated at room temperature for 20 min. The A405 of wells were measured on a microtitre plate reader (Genios using Magellan software) and results were analysed using GraphPad Prism, version 5.1 (GraphPad Software, San Diego).

EMSA

EMSA was performed as described previously (24). Proteins were incubated with double-stranded biotinylated NF-κB consensus oligonucleotide (5′-AGTTGAGGGGACTTTCCCAGGC-3′; MWG Biotech) for 30 min at room temperature in binding buffer (4% (v/v) glycerol, 1 mM EDTA, 10 mM Tris-HCl, pH 7.5, 100 mM NaCl, 5 mM DTT, and 0.1 mg/ml nuclease-free BSA) and 2 μg poly (dI-dC·dI-dC):poly(dI-dC·dI-dC) (Sigma-Aldrich). Reaction mixtures were electrophoresed on native 15% polyacrylamide gels. The gels were transferred to nitrocellulose in 1 X TBE for 30 min at 380 mA, 100 V, and then cross-linked on a UV transilluminator for 10 min. Detection of SLPI:DNA complexes was performed using the Chemiluminescent Nucleic Acid Detection Module (Pierce Chemical Co.). In brief, after crosslinking, the blot was incubated in blocking buffer for 1 h at 37°C. Streptavidin-peroxidase was added for 15 min in blocking buffer at room temperature, and the blot was then washed six times in wash buffer. The blot was incubated for 5 min in equilibration buffer and developed with the chemiluminescent reagents provided with the kit. SLPI:DNA binding was analysed using the Syngene GeneSnap and GeneTools software on the ChemiDoc system.

Evaluation of the antiprotease activity of NE-cleaved SLPI

To evaluate the antiprotease activity of NE-cleaved SLPI, we tested the ability of cleaved SLPI to inhibit one of its target proteases CatG. NE (13.3 μM) was incubated with SLPI (3.33 μM) in HEPES/NaCl buffer for 6 h after which NE activity was inactivated with the addition of 1 mM MeOSuc-AAPV-CMK. Samples approximating to 0.166 μM and 0.666 μM SLPI were withdrawn from the mixture and incubated with CatG (0.333 μM) in HEPES/NaCl buffer for 30 minutes. After this time, CatG substrate MeOSuc-AAPM-pNA (1 mM) was added to the samples and turnover of substrate evaluated at 405 nm over a 15 minute period. Delta absorbance values were converted to the amount of paranitroaniline produced as an indicator of CatG activity. Control reactions included NE-cleaved SLPI (666 nM) incubated with CatG substrate alone and CatG (0.333 μM) alone.

Results

Levels of SLPI in CF BALF

SLPI levels in BALF from 11 CF patients with Pseudomonas infection and 15 CF patients not infected with Pseudomonas were determined by ELISA. As shown in Fig. 1A, levels of SLPI were found to be significantly lower in P. aeruginosa-positive CF BALF (Ps+) compared with P. aeruginosa-negative BALF (Ps−) (3.99 ± 2.11 nM versus 15.62 ±5.74 nM, P<0.05). Analysis of SLPI in Ps− and Ps+ CF BALF by Western blot revealed distinctive banding patterns between the samples. As illustrated in Fig. 1B, in the absence of Pseudomonas infection, SLPI remains intact and a full length protein of approximately 12 kDa is detected. However, in Ps+ BALF samples, cleaved SLPI and lower levels of full length SLPI were found, suggesting that lower SLPI levels found in Ps+ BALF are a consequence of degradation.

Figure 1
SLPI levels and integrity in CF bronchoalveolar lavage fluid

Effects of CF BALF incubation on recombinant SLPI integrity

The effects of P. aeruginosa negative (Ps−) and P. aeruginosa positive (Ps+) CF BALF on the integrity of recombinant SLPI were investigated to determine and compare their ability to cleave SLPI. Recombinant SLPI was incubated with Ps− and Ps+ CF BALF for various times at 37°C and analysed by Western blot. As shown in Fig. 2, the levels of recombinant SLPI detected decreased in Ps+ CF BALF but not Ps− BALF over time. This degradation was visible but not complete after 1 h with the presence of an upper band displaying a similar size to intact SLPI and a lower band corresponding to proteolytic fragments of SLPI. However, after 6 and 24 h, proteolysis is almost complete with no intact SLPI detectable in the samples, only the presence of a lower band could be visualised. Recombinant SLPI was incubated separately in the absence of CF BALF under the same conditions and no degradation was detected. SLPI incubated in the presence of Ps− CF BALF showed no obvious signs of cleavage. These findings show that the proteolytic activity directed against SLPI was higher in Ps+ than in Ps− CF BALF.

Figure 2
Effects of Pseudomonas-infected and non-infected BALF fluid on the integrity of recombinant human SLPI

Identification of the protease family involved in the cleavage of SLPI in CF BALF

In order to identify the protease family involved in the cleavage of SLPI, Ps+ CF BALF samples were pre-incubated with different non-specific protease inhibitors targeting the serine, cysteine or metalloprotease families before adding recombinant SLPI in buffer at pH 7.5. After 24 h incubation at 37°C, samples were analysed by Western blot for SLPI. As shown in Fig. 3A, PMSF – a non-specific serine protease inhibitor – inhibits SLPI cleavage in Ps+ CF BALF, whereas neither the cysteine protease inhibitor E64 nor the metalloproteinase inhibitor EDTA had any effect. When this incubation was repeated at a lower pH (5.5), SLPI degradation was still prevented by PMSF but not EDTA or E64 (Fig. 3B). Overall, these findings show that non-specific inhibition of serine proteases in Ps+ CF BALF prevented cleavage of SLPI.

Figure 3
Effects of various protease inhibitors and pH on Ps+ BALF-induced cleavage of SLPI

Identification of the serine protease(s) involved in the cleavage of SLPI in CF BALF

Given the previous findings, we expanded the number of serine protease inhibitors used in order to further classify the putative serine protease that mediates the Ps+ CF BALF cleavage of SLPI. The inhibitors chosen target various groups of serine proteases (NE, Pr3 and CatG) with different efficacies. ACT inhibits CatG and chymase, elafin inhibits elastase and Pr3, and MeOSuc-AAPV-CMK specifically targets elastase. As shown in Fig. 4A, ACT did not prevent SLPI cleavage. In contrast, elafin and MeOSuc-AAPV-CMK completely inhibited SLPI cleavage in Ps+ CF BALF indicating that NE is most likely to be the serine protease responsible for SLPI cleavage in Ps+ CF BALF.

Figure 4
Effects of serine proteases and serine protease inhibitors on Ps+ BALF-induced cleavage of SLPI

The ability of purified human neutrophil serine proteases to cleave SLPI was evaluated in vitro to clarify which protease is mediating the cleavage observed. Recombinant SLPI was incubated with purified proteases and analysed by Western blot. A dose-response experiment was carried out for 1 h at 37°C using an increasing concentration of protease. As shown in Fig. 4B, incubating recombinant SLPI with NE, Pr3 and CatG resulted in the appearance of SLPI cleavage products a dose-dependent manner. However, when the cleavage patterns are compared with those illustrated in Fig. 2 following SLPI/Ps+ CF BALF incubations, only NE and CatG produce a similar pattern of cleavage products to that found following incubation of SLPI with Ps+ CF BALF. When SLPI was incubated with Pr3, proteolysis is almost complete with no intact SLPI detectable in the samples at the higher doses used in contrast to the banding pattern found with NE and CatG. However, as shown in Fig. 4A, the CatG inhibitor ACT does not inhibit Ps+ CF BALF mediated cleavage of SLPI (Fig. 4A) indicating that NE is the serine protease involved in the cleavage of SLPI by Ps+ CF BALF.

Measurement of NE Activity in CF BALF

Given that NE is responsible for the pattern of cleavage of SLPI in Ps+ CF BALF, and that the inhibitor is more rapidly degraded in Ps+ than in Ps− CF BALF, NE activity was measured in both CF BALF samples using the chromogenic substrate MeOSuc-AAPV-pNA. Elastase activity in CF BALF was calculated using a standard curve of purified NE to determine the concentration of free NE in samples. As shown in Fig. 5, the concentration of free NE is increased more than 9-fold in Ps+ compared to Ps− CF BALF (18.76 vs 1.92 μM, Fig. 5). Additionally, free elastase activity in both samples is totally abrogated using the NE inhibitor MeOSuc-AAPV-CMK (Fig. 5), thus confirming the specificity of the measurements. These results reinforce our finding that NE is responsible for SLPI cleavage in Ps+ CF BALF.

Figure 5
Free neutrophil elastase activity in Pseudomonas negative and positive CF BALF

Analysis of NE-SLPI cleavage sites

To further investigate the elastase-mediated cleavage of SLPI, products from NE-SLPI incubations were analysed by HPLC and mass spectrometry. HPLC separation of SLPI products generated within 2 h by an excess of NE resulted in the formation of three distinct peaks (Fig. 6A, peaks 1, 2 and 3). Identification of SLPI fragments was carried out by analysing peaks in mass spectrometry. The deconvoluted mass of peak 1 was 10,152 Da identifying it as SLPI residues Glu17-Ala107 (calculated mass = 10,152 Da). Likewise, the measured mass for the peak 2 was 10,223 Da identifying it as SLPI residues Ala16-Ala107 (calculated mass = 10223.14 Da). The measured mass of peak 3 was 11,725 Da identifying it as full-length SLPI residues Ser1-Ala107 (calculated mass = 11725.93 Da). These results indicate that 2-fold excess of NE cleaved SLPI at the Ser15-Ala16 and Ala16-Glu17 peptide bonds. In contrast, such cleavages were not detected using conditions with a slight excess of SLPI ([enzyme]:[inhibitor] molar ratio = 1:2.5), even after 24 h of incubation (data not shown). Taken together, these findings indicate that NE-mediated cleavage of SLPI occurs only with excess of NE. The cleavage sites generated by NE within SLPI are summarised in Fig. 6B.

Figure 6
HPLC analysis of SLPI incubated with neutrophil elastase

Effects of excess NE on SLPI functions

In addition to its antiprotease capabilities, SLPI has anti-bacterial and anti-inflammatory effects and can interact with the endotoxin LPS of Gram-negative bacteria such as E. coli and modulate macrophage responses after LPS stimulation (2123). We therefore investigated the effect of NE-induced cleavage on the ability of SLPI to bind LPS. Recombinant SLPI was incubated alone or with an excess of NE and examined for its capacity to bind to P. aeruginosa LPS by ELISA. As illustrated in Fig. 7A, intact SLPI was able to interact with P. aeruginosa LPS in a dose-dependent manner. In contrast, little or no SLPI-LPS binding was detected when SLPI pre-treated with NE or untreated NE were analysed. Thus, these results suggest that NE suppresses the ability of SLPI to bind to P. aeruginosa LPS. Similar findings were obtained when E. coli LPS was used (data not shown). SLPI can inhibit LPS-induced pro-inflammatory responses in monocytes and macrophages, and previous work from our group has found that SLPI exerts inhibitory effects on nuclear events of the LPS-induced NF-κB signalling cascade by competing with NF-κB p65 for binding to the NF-κB binding sites in the promoter region of genes such as IL-8 and TNF-α (24). Therefore, we investigated whether NE-cleaved SLPI was able to bind NF-κB consensus oligonucleotides. The results show that while intact SLPI binds biotinylated NF-κB oligonucleotide, SLPI incubated with an excess of NE or NE alone do not bind to the oligonucleotides (Fig. 7B). Overall, these findings suggest that NE abrogates a number of mechanisms by which SLPI exerts its anti-inflammatory functions.

Figure 7
Effects of neutrophil elastase on SLPI’s functional activities

Evaluation of the antiprotease activity of NE-cleaved SLPI

In order to determine the effect of NE cleavage on SLPI’s antiprotease activity, we evaluated the ability of NE-cleaved SLPI to inhibit CatG using the CatG specific substrate MeOSuc-AAPM-pNA. As before, SLPI was incubated with excess NE and cleavage of SLPI was confirmed by Western blot (data not shown). Samples were withdrawn from the mixture and incubated with a fixed amount of CatG (0.333 μM) – a sub-inhibitory sample (equivalent of 0.166 μM cleaved SLPI) and a 2-fold excess sample (equivalent of 0.666 μM cleaved SLPI). As illustrated in Figure 8, the sub-inhibitory sample of NE-cleaved SLPI reduced CatG activity and the 2-fold excess sample of cleaved SLPI almost completely abolished CatG activity, similar to that observed with 2-fold excess of native full length SLPI. Therefore, NE-cleaved SLPI retains its antiprotease activity against its target serine protease CatG.

Figure 8
NE-cleaved SLPI retains its ability to inhibit activity of the serine protease cathepsin G

Discussion

CF is characterised by chronic lung disease and recurrent bacterial infection. Infection with P. aeruginosa is associated with increased morbidity and mortality in patients with CF. Typically respiratory secretions are rich in multifunctional innate immunity proteins and peptides such as lactoferrin, LL-37, β-defensins, elafin and SLPI. However, during lung inflammation it appears that a number of these host defence components are sensitive to exacerbated proteolytic activity emanating from dysregulated elastolytic enzymes as found in chronic lung diseases such as CF (27,28,30,31,3335). It is important that the cause of this proteolytic activity is elucidated to facilitate the development of more efficient and robust therapies and to enable our understanding of how CF progresses. In the upper respiratory tract SLPI is thought to be primarily involved in protecting against human NE-induced damage as it accounts for approximately 90% of the total molar concentration of elastase inhibitors in human bronchial secretions (36) and may in fact be up-regulated during times of inflammation. Nevertheless there is a growing wealth of evidence purporting that despite its putative proteolytically stable structure due to the number of disulfide bridges present, SLPI is in fact prone to cleavage by proteases of endogenous and bacterial origin.

In this study, we demonstrate the potent ability of P. aeruginosa-infected CF bronchial secretions to cleave exogenous recombinant human SLPI in an NE-dependent manner. In contrast, CF BALF from patients not infected with P. aeruginosa was not able to cleave SLPI. In vivo, SLPI concentrations have been found to be higher in upper respiratory airways than lower airways with reported levels of 0.1–0.2 μg/ml (8.33 – 16.66 nM) in BALF (29) and between 0.1–24 μg/ml (8.33 nM – 2 μM) in saliva (12,37,38). We have shown that SLPI levels in non-infected CF airways approximate to the values described previously for BALF (29). However, when chronic infection has taken hold, a significantly lower concentration of SLPI was detected in Pseudomonas-infected BALF (3.99 ± 2.11 nM).

A possible cause of this reduction in SLPI levels was identified following Western blotting analysis of BALF samples from Ps− and Ps+ CF patients, which revealed the presence of cleaved SLPI fragments of approximately 10 kDa in size in BALF from Ps+ patients. Although the majority of Ps− BALF samples displayed no evidence of SLPI cleavage, we detected the presence of cleavage products in two samples, suggesting that other proteases are present in these BALF samples which are capable of cleaving SLPI. The identity of this protease activity is unknown, however, we speculate that cathepsins may play a role given our previous demonstration of the ability of cathepsins to cleave SLPI (28). Overall, the findings suggest that the decrease in BALF SLPI levels as evidenced by ELISA is a consequence of degradation by factor(s) present in Ps+ but not Ps− BALF. We further investigated this phenomenon by comparing the effects of CF BALF from P. aeruginosa-infected and non-infected patients on the integrity of recombinant human SLPI. Previous work by Vogelmeier et al. (29) demonstrated the presence of cleaved SLPI in BALF from patients with CF, but no details of the status of Pseudomonas infection were provided in the study. Our findings expand this observation as we show that only Pseudomonas-infected BALF is capable of degrading SLPI. As Pseudomonas elastase (pseudolysin) has been reported to cleave SLPI (32), we examined the involvement of this bacterial protease by pre-treating P. aeruginosa-infected BALF with EDTA, which inhibits Pseudomonas elastase activity. Pre-treatment with EDTA was unable to inhibit P. aeruginosa-positive BALF-mediated cleavage of SLPI. However, we found that P. aeruginosa-positive BALF cleavage of SLPI was inhibited by the addition of human NE inhibitors (PMSF, elafin and MeOSuc-AAPV-CMK), thus implicating human NE in the process. When recombinant human SLPI was incubated with an excess of purified NE (molar ratio of [enzyme]:[inhibitor] 2:1), we observed a similar pattern of cleavage products to that found with P. aeruginosa-positive BALF.

Although CatG incubation with SLPI also gave a similar pattern of cleavage products to that obtained with NE and P. aeruginosa-positive BALF, ACT (which inhibits CatG and chymase) was unable to prevent this cleavage. Consequently, we concluded that neither CatG nor chymase mediated the cleavage we observed. Belkowski et al. (39) have reported the ability of chymase to cleave exogenous recombinant human SLPI at residues Leu72-Met73, the reactive site bond present in the second WFDC domain at the COOH-terminal of the protein. However, although chymase is known to be a major protease involved in asthma and allergic responses in the airway, the role of such mast cell proteases in CF has yet to be fully elucidated (40). Also, in contrast to our findings, Belkowski et al. (39) state that neither CatG nor Pr3 cleaved recombinant human SLPI, but a minor digestion product was reported following elastase incubation. A possible reason for this discrepancy is the molar ratios of [enzyme]:[inhibitor] used. Similar to Masuda et al. (41), we found that incubation of an equimolar ratio of [SLPI]:[NE] resulted in little or no cleavage of SLPI. However, once the concentration of NE was increased to a 2:1 molar ratio of [NE]:[SLPI], significant cleavage of SLPI was observed. Furthermore, in agreement with previous findings (42), incubation of SLPI with purified human Pr3 also cleaved SLPI. However, Western blot analysis revealed that no lower molecular weight cleaved SLPI fragments could be visualised, in contrast to the cleavage pattern found when SLPI was incubated with NE and CatG or Ps+ CF BALF –where the presence of a lower molecular weight band was detected. In addition, we have shown that NE activity is significantly elevated in Ps+ CF BALF compared to Ps− CF BALF and this activity is completely inhibited by the MeOSuc-AAPV-CMK, which is specific for NE, once again confirming that excess NE levels in Ps+ CF BALF are responsible for cleaving SLPI.

Further analysis of the NE-induced cleavage of SLPI revealed the presence of 2 cleavage sites at Ser15-Ala16 and Ala16-Glu17 in the NH2-terminus WFDC domain of the protein. Identification of Ser15-Ala16 as a cleavage site is in agreement with previous work by Masuda et al. (41) who reported the ability of excess NE to cleave SLPI at at least two sites, Ser15-Ala16 and Thr57-Arg58. These cleavage sites are in contrast to those we previously found for cathepsin-mediated cleavage of SLPI which occurred at Thr67-Tyr68 (28). We have previously demonstrated that cathepsin L in COPD BALF can cleave and inactivate SLPI, however, there is little or no NE activity in COPD BALF (28). In contrast, NE and cysteinyl cathepsin activity are both present in CF BALF (30). Nevertheless, we postulate that SLPI has a much greater affinity for NE than cathepsin L so in the Pseudomonas-infected lung, SLPI most likely binds preferentially to NE thus masking the Thr67-Tyr68 bond from cleavage by cathepsins. However, under these circumstances, excess NE can cleave SLPI at the NH2-terminus as we have shown in this report.

The implications of NE-induced cleavage of SLPI in vivo became evident from a number of functional studies in which we tested the ability of NE-cleaved SLPI to exert well-known anti-inflammatory functions such as binding to LPS and NF-κB consensus binding sites. Ding et al. demonstrated that recombinant human SLPI binds to E. coli LPS and prevents the formation of LPS-CD14 complexes and slows the transfer of LPS from the complexes to macrophages (23). Following incubation with NE, the ability of SLPI to bind P. aeruginosa and E. coli LPS was dramatically reduced, which may contribute to enhanced cellular responsiveness to LPS. In addition, we demonstrated that NE-cleaved SLPI is no longer capable of binding NF-κB consensus binding sites and is therefore unable to prevent NF-κB p65 binding and initiating pro-inflammatory cytokine expression as shown previously (24). Given that NE was found to cleave SLPI at two sites in the NH2-terminal, these findings suggest that this region of the SLPI protein plays a vital role in at least some of SLPI’s anti-inflammatory functions. Previous work has highlighted the importance of the NH2-terminal of SLPI in mediating its antimicrobial activities (14,43). Consequently, it is reasonable to hypothesise that in addition to inactivating important anti-inflammatory effects of SLPI, NE is also capable of dampening the anti-bacterial ability of SLPI. It is interesting to note however, that although NE can inactivate a number of SLPI’s anti-inflammatory mechanisms of action, it fails to significantly alter the ability of SLPI to inhibit one of its target serine proteases CatG. The preservation of antiprotease properties of SLPI fragments may be a result of its structure. The antiprotease active site of SLPI is located in a loop (residues 67–74) in the COOH-terminal WFDC domain. It has been reported that the recombinant COOH-terminal domain of SLPI retains its elastase inhibitory activity (41,44). As NE cleaves SLPI at the NH2-terminus, we would expect the resulting fragment to retain its anti-protease activity as confirmed by our findings above.

The susceptibility of SLPI to proteolytic degradation is a major hindrance in treating diseases characterised by a protease burden such as CF. Given the vicious cycle of infection, inflammation and proteolytic degradation that exists in CF, and the multifunctionality of SLPI, this protein is an obvious choice as a therapeutic for such a disease but findings to date reveal only limited success. Intravenous administration of recombinant SLPI to animals resulted in rapid renal clearance hindering their use as intravenous agents (45). As an alternative, aerosolised recombinant versions have been evaluated and were found to be effective both in terms of delivery and in mediating therapeutic effects (16). McElvaney et al. (16) demonstrated suppression of pulmonary NE and IL-8 levels following administration of aerosolised SLPI to CF patients. However, the use of SLPI in a clinical setting has been limited by enzymatic cleavage and failure to deposit efficiently in poorly ventilated, highly inflamed areas of the lung (46) and as such, clinical studies have yet to progress to the next stage. Recent work by Gibbons et al. (47) may present an effective alternative to remedy some of these obstacles. By encapsulating recombinant human SLPI in biocompatible liposomes, the stability of SLPI was improved in response to cysteine protease exposure, however, whether encapsulation protects from NE-induced degradation remains to be determined.

Overall, these novel findings broaden our understanding of the destruction caused by P. aeruginosa infection and how it contributes to chronic damage seen in the CF lung. Despite aggressive antibiotic treatments, pulmonary infection with P. aeruginosa remains a leading cause of morbidity and mortality in CF patients. Pseudomonas infection is associated with higher elastase concentrations, and proteases, particularly NE, contribute to the pathology of CF by impairing mucociliary clearance, interfering with innate immune functions, and perpetuating neutrophilic inflammation (1,48,49). Our results confirm and expand previous work demonstrating that excessive NE activity in the Pseudomonas-infected CF lung can cause the degradation of elafin, another serine antiprotease produced locally in the lung (34). In vivo, SLPI appears to be constitutively expressed and may provide a baseline host defence shield that can be up-regulated at times when inflammation or infection are anticipated (50). However, given its susceptibility to proteolytic degradation by not only cysteinyl proteases like cathepsins, but also the serine protease NE, the levels and biological activities may be compromised in vivo.

Footnotes

1The authors wish to acknowledge funding from the Northern Ireland Chest Heart and Stroke Association (CT 2008 107) and the American Alpha One Foundation.

3Abbreviations: AAT, alpha-1-antitrypsin; ACT, Alpha-1-antichymotrypsin; BALF, bronchoalveolar lavage fluid; CatG, cathepsin G; COPD, chronic obstructive pulmonary disease; CF, Cystic Fibrosis; MeOSuc-AAPM-pNA, N-(Methoxysuccinyl)-Ala-Ala-Pro-Met-paranitroanilide; MeOSuc-AAPV-CMK or CMK, N-(Methoxysuccinyl)-Ala-Ala-Pro-Val-chloromethyl ketone; MeOSuc-AAPV-pNA, N-(Methoxysuccinyl)-Ala-Ala-Pro-Val-paranitroanilide; NE, neutrophil elastase; Pr3, proteinase 3; Ps-, Pseudomonas negative; Ps+, Pseudomonas positive; SLPI, secretory leucoprotease inhibitor.

References

1. Voynow JA, Fischer BM, Zheng S. Proteases and cystic fibrosis. Int J Biochem Cell Biol. 2008;40:1238–1245. [PMC free article] [PubMed]
2. Courtney JM, Bradley J, McCaughan J, O’Connor TM, Shortt C, Bredin CP, Bradbury I, Elborn JS. Predictors of mortality in adults with cystic fibrosis. Pediatr Pulmonol. 2007;42:525–532. [PubMed]
3. Murray TS, Egan M, Kazmierczak BI. Pseudomonas aeruginosa chronic colonization in cystic fibrosis patients. Curr Opin Pediatr. 2007;19:83–88. [PubMed]
4. Seemüller U, Arnhold M, Fritz H, Wiedenmann K, Machleidt W, Heinzel R, Appelhans H, Gassen HG, Lottspeich F. The acid-stable proteinase inhibitor of human mucous secretions (HUSI-I, antileukoprotease). Complete amino acid sequence as revealed by protein and cDNA sequencing and structural homology to whey proteins and Red Sea turtle proteinase inhibitor. FEBS Lett. 1986;199:43–48. [PubMed]
5. Ranganathan S, Simpson KJ, Shaw DC, Nicholas KR. The whey acidic protein family: a new signature motif and three-dimensional structure by comparative modeling. J Mol Graph Model. 1999;17:106–113. 134–136. [PubMed]
6. Jin FY, Nathan C, Radzioch D, Ding A. Secretory leukocyte protease inhibitor: a macrophage product induced by and antagonistic to bacterial lipopolysaccharide. Cell. 1997;88:417–426. [PubMed]
7. Kammouni W, Figarella C, Baeza N, Marchand S, Merten MD. Pseudomonas aeruginosa lipopolysaccharide induces CF-like alteration of protein secretion by human tracheal gland cells. Biochem Biophys Res Commun. 1997;241:305–311. [PubMed]
8. van Wetering S, van der Linden AC, van Sterkenburg MA, Rabe KF, Schalkwijk J, Hiemstra PS. Regulation of secretory leukocyte proteinase inhibitor (SLPI) production by human bronchial epithelial cells: increase of cell-associated SLPI by neutrophil elastase. J Investig Med. 2000;48:359–366. [PubMed]
9. Saitoh H, Masuda T, Shimura S, Fushimi T, Shirato K. Secretion and gene expression of secretory leukocyte protease inhibitor by human airway submucosal glands. Am J Physiol Lung Cell Mol Physiol. 2001;280:L79–L87. [PubMed]
10. Vos JB, van Sterkenburg MA, Rabe KF, Schalkwijk J, Hiemstra PS, Datson NA. Transcriptional response of bronchial epithelial cells to Pseudomonas aeruginosa: identification of early mediators of host defense. Physiol Genomics. 2005;21:324–336. [PubMed]
11. Jin F, Nathan CF, Radzioch D, Ding A. Lipopolysaccharide-related stimuli induce expression of the secretory leukocyte protease inhibitor, a macrophage-derived lipopolysaccharide inhibitor. Infect Immun. 1998;66:2447–2452. [PMC free article] [PubMed]
12. Doumas S, Kolokotronis A, Stefanopoulos P. Anti-inflammatory and antimicrobial roles of secretory leukocyte protease inhibitor. Infect Immun. 2005;73:1271–1274. [PMC free article] [PubMed]
13. Wiedow O, Harder J, Bartels J, Streit V, Christophers E. Antileukoprotease in human skin: an antibiotic peptide constitutively produced by keratinocytes. Biochem Biophys Res Commun. 1998;248:904–909. [PubMed]
14. Hiemstra PS, Maassen RJ, Stolk J, Heinzel-Wieland R, Steffens GJ, Dijkman JH. Antibacterial activity of antileukoprotease. Infect Immun. 1996;64:4520–4524. [PMC free article] [PubMed]
15. Tomee JF, Hiemstra PS, Heinzel-Wieland R, Kauffman HF. Antileukoprotease: an endogenous protein in the innate mucosal defense against fungi. J Infect Dis. 1997;176:740–747. [PubMed]
16. McElvaney NG, Nakamura H, Birrer P, Hébert CA, Wong WL, Alphonso M, Baker JB, Catalano MA, Crystal RG. Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor. J Clin Invest. 1992;90:1296–1301. [PMC free article] [PubMed]
17. Vogelmeier C, Gillissen A, Buhl R. Use of secretory leukoprotease inhibitor to augment lung antineutrophil elastase activity. Chest. 1996;110:261S–266S. [PubMed]
18. Nakamura A, Mori Y, Hagiwara K, Suzuki T, Sakakibara T, Kikuchi T, Igarashi T, Ebina M, Abe T, Miyazaki J, Takai T, Nukiwa T. Increased susceptibility to LPS-induced endotoxin shock in secretory leukoprotease inhibitor (SLPI)-deficient mice. J Exp Med. 2003;197:669–674. [PMC free article] [PubMed]
19. Lentsch AB, Jordan JA, Czermak BJ, Diehl KM, Younkin EM, Sarma V, Ward PA. Inhibition of NF-kappaB activation and augmentation of IkappaBbeta by secretory leukocyte protease inhibitor during lung inflammation. Am J Pathol. 1999;154:239–247. [PubMed]
20. Mulligan MS, Lentsch AB, Huber-Lang M, Guo RF, Sarma V, Wright CD, Ulich TR, Ward PA. Anti-inflammatory effects of mutant forms of secretory leukocyte protease inhibitor. Am J Pathol. 2000;156:1033–1039. [PubMed]
21. McMichael JW, Roghanian A, Jiang L, Ramage R, Sallenave JM. The antimicrobial antiproteinase elafin binds to lipopolysaccharide and modulates macrophage responses. Am J Respir Cell Mol Biol. 2005;32:443–452. [PubMed]
22. Yang J, Zhu J, Sun D, Ding A. Suppression of macrophage responses to bacterial lipopolysaccharide (LPS) by secretory leukocyte protease inhibitor (SLPI) is independent of its anti-protease function. Biochim Biophys Acta. 2005;1745:310–317. [PubMed]
23. Ding A, Thieblemont N, Zhu J, Jin F, Zhang J, Wright S. Secretory leukocyte protease inhibitor interferes with uptake of lipopolysaccharide by macrophages. Infect Immun. 1999;67:4485–4489. [PMC free article] [PubMed]
24. Taggart CC, Cryan SA, Weldon S, Gibbons A, Greene CM, Kelly E, Low TB, O’Neill SJ, McElvaney NG. Secretory leucoprotease inhibitor binds to NF-kappaB binding sites in monocytes and inhibits p65 binding. J Exp Med. 2005;202:1659–1668. [PMC free article] [PubMed]
25. Taggart CC, Greene CM, McElvaney NG, O’Neill S. Secretory leucoprotease inhibitor prevents lipopolysaccharide-induced IkappaBalpha degradation without affecting phosphorylation or ubiquitination. J Biol Chem. 2002;277:33648–33653. [PubMed]
26. Greene CM, McElvaney NG, O’Neill SJ, Taggart CC. Secretory leucoprotease inhibitor impairs Toll-like receptor 2- and 4-mediated responses in monocytic cells. Infect Immun. 2004;72:3684–3687. [PMC free article] [PubMed]
27. Gompertz S, Bayley DL, Hill SL, Stockley RA. Relationship between airway inflammation and the frequency of exacerbations in patients with smoking related COPD. Thorax. 2001;56:36–41. [PMC free article] [PubMed]
28. Taggart CC, Lowe GJ, Greene CM, Mulgrew AT, O’Neill SJ, Levine RL, McElvaney NG. Cathepsin B, L, and S cleave and inactivate secretory leucoprotease inhibitor. J Biol Chem. 2001;276:33345–33352. [PubMed]
29. Vogelmeier C, Hubbard RC, Fells GA, Schnebli HP, Thompson RC, Fritz H, Crystal RG. Anti-neutrophil elastase defense of the normal human respiratory epithelial surface provided by the secretory leukoprotease inhibitor. J Clin Invest. 1991;87:482–488. [PMC free article] [PubMed]
30. Taggart CC, Greene CM, Smith SG, Levine RL, McCray PB, Jr, O’Neill S, McElvaney NG. Inactivation of human beta-defensins 2 and 3 by elastolytic cathepsins. J Immunol. 2003;171:931–937. [PubMed]
31. Rogan MP, Taggart CC, Greene CM, Murphy PG, O’Neill SJ, McElvaney NG. Loss of microbicidal activity and increased formation of biofilm due to decreased lactoferrin activity in patients with cystic fibrosis. J Infect Dis. 2004;190:1245–1253. [PubMed]
32. Johnson DA, Carter-Hamm B, Dralle WM. Inactivation of human bronchial mucosal proteinase inhibitor by Pseudomonas aeruginosa elastase. Am Rev Respir Dis. 1982;126:1070–1073. [PubMed]
33. Britigan BE, Hayek MB, Doebbeling BN, Fick RB., Jr Transferrin and lactoferrin undergo proteolytic cleavage in the Pseudomonas aeruginosa-infected lungs of patients with cystic fibrosis. Infect Immun. 1993;61:5049–5055. [PMC free article] [PubMed]
34. Guyot N, Butler MW, McNally P, Weldon S, Greene CM, Levine RL, O’Neill SJ, Taggart CC, McElvaney NG. Elafin, an elastase-specific inhibitor, is cleaved by its cognate enzyme neutrophil elastase in sputum from individuals with Cystic Fibrosis. J Biol Chem. 2008;283:32377–32385. [PubMed]
35. Taggart CC, Greene CM, Carroll TP, O’Neill SJ, McElvaney NG. Elastolytic proteases: inflammation resolution and dysregulation in chronic infective lung disease. Am J Respir Crit Care Med. 2005;171:1070–1076. [PubMed]
36. Tegner H. Quantitation of human granulocyte protease inhibitors in non-purulent bronchial lavage fluids. Acta Otolaryngol. 1978;85:282–289. [PubMed]
37. McNeely TB, Dealy M, Dripps DJ, Orenstein JM, Eisenberg SP, Wahl SM. Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J Clin Invest. 1995;96:456–464. [PMC free article] [PubMed]
38. Chattopadhyay A, Gray LR, Patton LL, Caplan DJ, Slade GD, Tien HC, Shugars DC. Salivary secretory leukocyte protease inhibitor and oral candidiasis in human immunodeficiency virus type 1-infected persons. Infect Immun. 2004;72:1956–1963. [PMC free article] [PubMed]
39. Belkowski SM, Masucci J, Mahan A, Kervinen J, Olson M, de Garavilla L, D’Andrea MR. Cleaved SLPI, a novel biomarker of chymase activity. Biol Chem. 2008;389:1219–1224. [PubMed]
40. Sallenave JM. The role of secretory leukocyte proteinase inhibitor and elafin (elastase-specific inhibitor/skin-derived antileukoprotease) as alarm antiproteinases in inflammatory lung disease. Respir Res. 2000;1:87–92. [PMC free article] [PubMed]
41. Masuda KI, Suga M, Takeuchi A, Kanesaki M, Imaizumi A, Suzuki Y. Specific cleavage of secretory leukoprotease inhibitor by neutrophil elastase and saliva. Biochem Pharmacol. 1994;48:651–657. [PubMed]
42. Rao NV, Marshall BC, Gray BH, Hoidal JR. Interaction of secretory leukocyte protease inhibitor with proteinase-3. Am J Respir Cell Mol Biol. 1993;8:612–616. [PubMed]
43. Fernie-King BA, Seilly DJ, Davies A, Lachmann PJ. Streptococcal inhibitor of complement inhibits two additional components of the mucosal innate immune system: secretory leukocyte proteinase inhibitor and lysozyme. Infect Immun. 2002;70:4908–4916. [PMC free article] [PubMed]
44. Kramps JA, van Twisk C, Appelhans H, Meckelein B, Nikiforov T, Dijkman JH. Proteinase inhibitory activities of antileukoprotease are represented by its second COOH-terminal domain. Biochem Biophys Acta. 1990;1038:178–185. [PubMed]
45. Bergenfeldt M, Björk P, Ohlsson K. The elimination of secretory leukocyte protease inhibitor (SLPI) after intravenous injection in dog and man. Scand J Clin Lab Invest. 1990;50:729–737. [PubMed]
46. Stolk J, Camps J, Feitsma HI, Hermans J, Dijkman JH, Pauwels EK. Pulmonary deposition and disappearance of aerosolised secretory leucocyte protease inhibitor. Thorax. 1995;150:645–650. [PMC free article] [PubMed]
47. Gibbons AM, McElvaney NG, Taggart CC, Cryan SA. Delivery of rSLPI in a liposomal carrier for inhalation provides protection against cathepsin L degradation. J Microencapsul. 2008;26:513–522. [PubMed]
48. Dosanjh AK, Elashoff D, Robbins RC. The bronchoalveolar lavage fluid of cystic fibrosis lung transplant recipients demonstrates increased interleukin-8 and elastase and decreased IL-10. J Interferon Cytokine Res. 1998;18:851–854. [PubMed]
49. Douglas TA, Brennan S, Gard S, Berry L, Gangell C, Stick SM, Clements BS, Sly PD. Acquisition and eradication of P. aeruginosa in young children with Cystic Fibrosis. Eur Respir J. 2009;33:305–311. [PubMed]
50. Williams SE, Brown TI, Roghanian A, Sallenave JM. SLPI and elafin: one glove, many fingers. Clin Sci (Lond) 2006;110:21–35. [PubMed]